ReviewCancer cell international2026
LncRNA NKILA as a key regulator in cancer pathogenesis: insights into its mechanisms and clinical implications.
Review in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The NF-κB interacting LncRNA (NKILA) is a recently identified long noncoding RNA (lncRNA) located on chromosome 20q13.31. Studies have indicated that abnormal levels of NKILA expression in different types of cancer can function as either oncogenes or tumour suppressors and play a role in the development of diverse malignancies. Moreover, NKILA expression levels correlate closely with the clinical features and prognosis of cancer patients, underscoring its potential significance in clinical practice. Multiple studies have shown that NKILA acts as a competing endogenous RNA (ceRNA), participating in several crucial signalling pathways and interacting with proteins to regulate gene expression. Furthermore, NKILA affects essential aspects of cancer cell behaviour, such as proliferation, migration, invasion, apoptosis, the epithelial-mesenchymal transition (EMT), and resistance to treatment. NKILA downregulation is associated with increased tumour size, advanced pathological stage, increased lymph node metastasis, and poor patient prognosis. This article reviews the expression patterns, clinical relevance, molecular mechanisms, and biological functions of NKILA, investigates its potential clinical roles as a therapeutic target and diagnostic marker, and evaluates its efficacy in treating various tumours.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.